Eric Weisman, MD
Neurology · Pittsburgh, PANPI 1124051156
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,255 of the $4,711 with a category attached, or 69.1%. Biogen accounts for 82.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $3,674 and has fallen 86.5% since, to $494 in 2025.
Across 59 payments — averaging $79.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$4K
- Eisai Inc.$561
- Lilly USA, LLC$248
- Life Molecular Imaging Ltd$18
- Amgen$16
What the payments were for
- Speaking & faculty fees$3,25569%
- Food & beverage$1,45631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 12 | $3,869 |
| Eisai Inc. | 31 | $561 |
| Lilly USA, LLC | 14 | $248 |
| Life Molecular Imaging Ltd | 1 | $18 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADUHELM$117
How this compares
$4,711 in reported general payments places this provider in the 70th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 126 | $21,038 |
| RexultiBrexpiprazole | 12 | $18,253 |
| Donepezil Hcl | 1,835 | $12,409 |
| Memantine Hcl | 457 | $11,734 |
| Lamotrigine | 402 | $4,607 |
| Risperidone OdtRisperidone | 13 | $2,127 |
| Selegiline Hcl | 13 | $2,084 |
| Lacosamide | 17 | $2,016 |
| Carbamazepine ErCarbamazepine | 24 | $1,607 |
| Levetiracetam | 104 | $1,391 |
| Divalproex Sodium ErDivalproex Sodium | 48 | $1,373 |
| Gabapentin | 83 | $1,362 |
| Sertraline Hcl | 296 | $1,149 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 24 | $991 |
| Quetiapine Fumarate | 114 | $880 |
Paid to pharmacies, not to this prescriber.
Other neurology in Pittsburgh
- Anoopum GuptaPittsburgh$592K
- Thomas ScottPittsburgh$476K
- James ValerianoPittsburgh$416K
- Amber van LaarPittsburgh$413K
- Andrea SynowiecPittsburgh$386K
- Dolores Dominguez SantamariaPittsburgh$265K
- Heather MouryPittsburgh$186K
- Troy DesaiPittsburgh$174K
- Richard KasdanPittsburgh$172K
- David LobasPittsburgh$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.